Avammune Therapeutics

Developer of small-molecule innate immune modulators for cancer therapy. It discovers and develops orally available drug candidates that target enzymes and pathways in the innate immune system to treat solid tumors and autoimmune diseases. Its pipeline includes AVA-NP-695 which is ENPP inhibitors and AVA-ADR-001 ADAR inhibitors designed to provide antitumor activity and synergy with checkpoint inhibitors and radiation.